Preamble
The medical profession should play a central role in evaluating the evidence related to drugs, devices, and procedures for the detection, management, and prevention of disease. When properly applied, expert analysis of available data on the benefits and risks of these therapies and procedures can improve the quality of care, optimize patient outcomes, and favorably affect costs by focusing resources on the most effective strategies. An organized and directed approach to a thorough review of evidence has resulted in the production of clinical practice guidelines that assist physicians in selecting the best management strategy for an individual patient. Moreover, clinical practice guidelines can provide a foundation for other applications, such as performance measures, appropriate use criteria, and both quality improvement and clinical decision support tools.
The American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have jointly produced guidelines in the area of cardiovascular disease since 1980. The ACCF/AHA Task Force on Practice Guidelines (Task Force), charged with developing, updating, and revising practice guidelines for cardiovascular diseases and procedures, directs and oversees this effort. Writing committees are charged with regularly reviewing and evaluating all available evidence to develop balanced, patientcentric recommendations for clinical practice.
Experts in the subject under consideration are selected by the ACCF and AHA to examine subject-specific data and write guidelines in partnership with representatives from other medical organizations and specialty groups. Writing committees are asked to perform a literature review; weigh the strength of evidence for or against particular tests, treatments, or procedures; and include estimates of expected outcomes where such data exist. Patient-specific modifiers, comorbidities, and issues of patient preference that may influence the choice of tests or therapies are considered. When available, information from studies on cost is considered, but data on efficacy and outcomes constitute the primary basis for the recommendations contained herein.
In analyzing the data and developing recommendations and supporting text, the writing committee uses evidencebased methodologies developed by the Task Force (1) . The Class of Recommendation (COR) is an estimate of the size of the treatment effect, with consideration given to risks versus benefits in addition to evidence and/or agreement that a given treatment or procedure is or is not useful/ effective or in some situations may cause harm. The Level of Evidence (LOE) is an estimate of the certainty or precision of the treatment effect. The writing committee reviews and ranks evidence supporting each recommendation, with the weight of evidence ranked as LOE A, B, or C according to specific definitions that are included in Table 1 . Studies are identified as observational, retrospective, prospective, or randomized as appropriate. For certain conditions for which inadequate data are available, recommendations are based on expert consensus and clinical experience and are ranked as LOE C. When recommendations at LOE C are supported by historical clinical data, appropriate references (including clinical reviews) are cited if available. For issues for which sparse data are available, a survey of current practice among the clinicians on the writing committee is the basis for LOE C recommendations, and no references are cited. The schema for COR and LOE is summarized in Table 1 , which also provides suggested phrases for writing recommendations within each COR. A new addition to this methodology is separation of the Class III recommendations to delineate whether the recommendation is determined to be of "no benefit" or is associated with "harm" to the patient. In addition, in view of the increasing number of comparative effectiveness studies, comparator verbs and suggested phrases for writing recommendations for the comparative effectiveness of one treatment or strategy versus another have been added for COR I and IIa, LOE A or B only.
In view of the advances in medical therapy across the spectrum of cardiovascular diseases, the Task Force has designated the term guideline-directed medical therapy (GDMT) to represent optimal medical therapy as defined by ACCF/AHA guideline-recommended therapies (primarily Class I). This new term, GDMT, will be used herein and throughout all future guidelines.
Because the ACCF/AHA practice guidelines address patient populations (and healthcare providers) residing in North America, drugs that are not currently available in North America are discussed in the text without a specific COR. For studies performed in large numbers of subjects outside North America, each writing committee reviews the potential influence of different practice patterns and patient populations on the treatment effect and relevance to the ACCF/AHA target population to determine whether the findings should inform a specific recommendation.
The ACCF/AHA practice guidelines are intended to assist healthcare providers in clinical decision making by describing a range of generally acceptable approaches to the diagnosis, management, and prevention of specific diseases or conditions. The guidelines attempt to define practices that meet the needs of most patients in most circumstances. The ultimate judgment about care of a particular patient must be made by the healthcare provider and patient in light of all the circumstances presented by that patient. As a result, situations may arise in which deviations from these guidelines might be appropriate. Clinical decision making should involve consideration of the Table 1 
. Applying Classification of Recommendations and Level of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
‫ء‬Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use. †For comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated. 4 Fihn et al. JACC Vol. 60, No. 24, 2012 Stable Ischemic Heart Disease: Executive Summary December 18, 2012:xxx quality and availability of expertise in the area where care is provided. When these guidelines are used as the basis for regulatory or payer decisions, the goal should be improvement in quality of care. The Task Force recognizes that situations arise in which additional data are needed to inform patient care more effectively; these areas will be identified within each respective guideline when appropriate. Prescribed courses of treatment in accordance with these recommendations are effective only if followed. Because lack of patient understanding and adherence may adversely affect outcomes, physicians and other healthcare providers should make every effort to engage the patient's active participation in prescribed medical regimens and lifestyles. In addition, patients should be informed of the risks, benefits, and alternatives to a particular treatment and should be involved in shared decision making whenever feasible, particularly for COR IIa and IIb, for which the benefit-to-risk ratio may be lower.
The Task Force makes every effort to avoid actual, potential, or perceived conflicts of interest that may arise as a result of industry relationships or personal interests among the members of the writing committee. All writing committee members and peer reviewers of this guideline were required to disclose all such current healthcare-related relationships, as well as those existing 24 months (from 2005) before initiation of the writing effort. The writing committee chair may not have any relevant relationships with industry or other entities (RWI); however, RWI are permitted for the vice chair position. In December 2009, the ACCF and AHA implemented a new policy that requires a minimum of 50% of the writing committee have no relevant RWI; in addition, the disclosure term was changed to 12 months before writing committee initiation. The present guideline was developed during the transition in RWI policy and occurred over an extended period of time. In the interest of transparency, we provide full information on RWI existing over the entire period of guideline development, including delineation of relationships that expired more than 24 months before the guideline was finalized. This information is included in Appendix 1. These statements are reviewed by the Task Force and all members during each conference call and meeting of the writing committee and are updated as changes occur. All guideline recommendations require a confidential vote by the writing committee and must be approved by a consensus of the voting members. Members who recused themselves from voting are indicated in the list of writing committee members, and section recusals are noted in Appendix 1. Authors' and peer reviewers' RWI pertinent to this guideline are disclosed in Appendixes 1 and 2, respectively. Comprehensive disclosure information for the Task Force is also available online at http://www.cardiosource.org/ACC/ About-ACC/Who-We-Are/Leadership/Guidelines-and-Documents-Task-Forces.aspx. The work of the writing committee is supported exclusively by the ACCF, AHA, American College of Physicians (ACP), American Associ-ation for Thoracic Surgery (AATS), Preventive Cardiovascular Nurses Association (PCNA), Society for Cardiovascular Angiography and Interventions (SCAI), and Society of Thoracic Surgeons (STS), without commercial support. Writing committee members volunteered their time for this activity.
The recommendations in this guideline are considered current until they are superseded by a focused update or the full-text guideline is revised. The reader is encouraged to consult the full-text guideline (2) for additional guidance and details about stable ischemic heart disease since the Executive Summary contains only the recommendations. Guidelines are official policy of both the ACCF and AHA.
Jeffrey L. Anderson, MD, FACC, FAHA Chair, ACCF/AHA Task Force on Practice Guidelines 1. Introduction
Methodology and Evidence Overview
The recommendations listed in this document are, whenever possible, evidence based. An extensive evidence review was conducted as the document was compiled through December 2008. Repeated literature searches were performed by the guideline development staff and writing committee members as new issues were considered. When available, current and credible meta-analyses were used instead of conducting a systematic review of all primary literature. New clinical trials published in peer-reviewed journals and articles through December 2011 were also reviewed and incorporated when relevant. Furthermore, because of the extended development time period for this guideline, peer review comments indicated that the sections focused on imaging technologies required additional updating, which occurred during 2011. Therefore, the evidence review for the imaging sections includes published literature through December 2011.
Searches were limited to studies, reviews, and other evidence in human subjects and published in English. Key search words included, but were not limited to: accuracy, angina, asymptomatic patients, cardiac magnetic resonance (CMR), cardiac rehabilitation, chest pain, chronic angina, chronic coronary occlusions, chronic ischemic heart disease (IHD), chronic total occlusion, connective tissue disease, coronary artery bypass graft (CABG) versus medical therapy, coronary artery disease (CAD) and exercise, coronary calcium scanning, cardiac/coronary computed tomography angiography (CCTA), CMR angiography, CMR imaging, coronary stenosis, death, depression, detection of CAD in symptomatic patients, diabetes, diagnosis, dobutamine stress echocardiography, echocardiography, elderly, electrocardiogram (ECG) and chronic stable angina, emergency department, ethnic, exercise, exercise stress testing, follow-up testing, gender, glycemic control, hypertension, intravascular ultrasound, fractional flow reserve, invasive coronary angiography, kidney disease, low-density lipoprotein lowering, magnetic resonance imaging (MRI), medication adherence, minority groups, mortality, myocardial infarction (MI), noninvasive testing and mortality, nuclear myocardial perfusion, nutrition, obesity, outcomes, patient follow-up, patient education, prognosis, proximal left anterior descending (LAD) disease, physical activity, reoperation, risk stratification, smoking, stable ischemic heart disease (SIHD), stable angina and reoperation, stable angina and revascularization, stress echocardiography, radionuclide stress testing, stenting versus CABG, unprotected left main, weight reduction, and women.
Organization of the Writing Committee
The writing committee was composed of physicians, cardiovascular interventionalists, surgeons, general internists, imagers, nurses, and pharmacists. The writing committee included representatives from the ACP, AATS, PCNA, SCAI, and STS.
Document Review and Approval
This document was reviewed by 2 external reviewers nominated by both the ACCF and the AHA; 2 reviewers nominated by the ACP, AATS, PCNA, SCAI, and STS; and 19 content reviewers, including representatives from the ACCF Imaging Council, ACCF Interventional Scientific Council, and the AHA Council on Clinical Cardiology. All reviewer RWI information was collected and distributed to the writing committee and is published in this document (Appendix 2). Because extensive peer review comments resulted in substantial revision, the guideline was subjected to a second peer review by all official and organizational reviewers.
Lastly, the imaging sections were also peer reviewed separately, after an update to that evidence base.
This document was approved for publication by the governing bodies of the ACCF, AHA, ACP, AATS, PCNA, SCAI, and STS.
Scope of the Guideline
These guidelines are intended to apply to adult patients with stable known or suspected IHD, including new-onset chest pain (i.e., low-risk unstable angina [UA]), or to adult patients with stable pain syndromes ( Figure 1 ). Patients who have "ischemic equivalents," such as dyspnea or arm pain with exertion, are included in the latter group. Many patients with IHD can become asymptomatic with appropriate therapy. Accordingly, the follow-up sections of this guideline pertain to patients who were previously symptomatic, including those who have undergone percutaneous coronary intervention (PCI) or CABG.
This guideline also addresses the initial diagnostic approach to patients who present with symptoms that suggest IHD, such as anginal-type chest pain, but who are not known to have IHD. In this circumstance, it is essential that the practitioner ascertain whether such symptoms represent the initial clinical recognition of chronic stable angina, reflecting gradual progression of obstructive CAD or an increase in supply/demand mismatch precipitated by a change in activity or concurrent illness (such as anemia or infection), or whether they represent an acute coronary syndrome (ACS), most likely due to an unstable plaque causing acute thrombosis. For patients with newly diagnosed stable angina, this guideline should be used. For patients with acute MI, the reader is referred to the ACCF/AHA guidelines for the management of patients with ST-elevation MI (3, 4) , and for patients with UA, the reader is referred to the "ACCF/AHA Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction" (5,5a). There are, however, patients with UA who can be categorized as low risk and are addressed in this guideline ( Table 2) .
A key premise of this guideline is that once a diagnosis of IHD is established, it is necessary in most patients to assess their risk of subsequent complications, such as acute myocardial infarction or death. Because the approach to diagnosis of suspected IHD and the assessment of risk in a patient with known IHD are conceptually different and are based on different literature, these issues are addressed separately. A clinician might, however, select a procedure for a patient with a moderate to high pretest likelihood of IHD to provide information for both diagnosis and risk assessment, whereas in a patient with a low likelihood of IHD, it could be sensible to select a test simply for diagnostic purposes without regard to risk assessment. The purpose of this dichotomy is to promote the sensible application of appropriate testing rather than routine use of the most expensive or complex tests whether warranted or not.
Additionally, this guideline addresses the approach to asymptomatic patients with SIHD that has been diagnosed solely on the basis of an abnormal screening study, rather than on the basis of clinical symptoms or events such as anginal symptoms or ACS. Multiple ACCF/AHA guidelines and scientific statements have discouraged the use of ambulatory monitoring, treadmill testing, stress echocardiography, stress myocardial perfusion imaging (MPI), and computed tomography scoring of coronary calcium or coronary angiography as routine screening tests in asymptomatic individuals.
When patients with documented IHD develop recurrent chest pain, the symptoms still could be attributable to another condition. Such patients are included in this guideline if there is sufficient suspicion that their heart disease is a likely source of symptoms to warrant cardiac evaluation. Just as in the case of patients with new-onset chest pain, if the pain seems to be cardiac in origin, the clinician must determine whether such recurrent or worsening pain is consistent with ACS or simply represents symptoms more consistent with chronic stable angina that do not require emergent attention.
The approach to screening and management of asymptomatic patients who are at risk for IHD but who are not known to have IHD is beyond the scope of this guideline, but it is addressed in the "ACCF/AHA Guideline for 
Assessment of Cardiovascular Risk in Asymptomatic
Adults" (6). Similarly, the present guideline does not apply to patients with chest pain symptoms early after revascularization, that is, within 6 months of revascularization.
General Approach and Overlap With Other Guidelines or Statements
This guideline overlaps with numerous clinical practice guidelines published by the ACCF/AHA Task Force on Practice Guidelines; the National Heart, Lung, and Blood Institute; and the ACP ( Table 3) . To maintain consistency, the writing committee worked with members of other committees to harmonize recommendations and eliminate discrepancies. This document recommends a combination of lifestyle modifications and medications that constitute GDMT. Recommendations for risk reduction are consistent with the "AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Vascular Disease: 2011 Update" (8). Recommendations related to revascularization are the result of collaboration discussions among several writing committees, including those addressing SIHD, PCI, CABG, and unstable angina/non-STelevation MI. To the fullest extent possible, these guidelines are consistent with the appropriate use criteria documents for imaging testing, diagnostic catheterization, and coronary revascularization that are also sponsored by the ACCF (9 -14).
Magnitude of the Problem
It is estimated that 1 in 3 adults in the United States (about 71 million) has some form of cardiovascular disease, including Ͼ13 million with CAD and nearly 9 million with angina pectoris (26, 27) . Among persons 60 to 79 years of age, approximately 23% of men and 15% of women have prevalent IHD, and these figures rise to 33% and 22% among men and women Ն80 years of age, respectively (27) .
Although the survival rate of patients with IHD has been steadily improving (28) , it was still responsible for nearly 380,000 deaths during the United States in 2010, with an age-adjusted mortality rate of 113 per 100,000 population (29) . Although IHD is widely known to be the number 1 cause of death in men, this is also the case for women, among whom this condition accounts for 27% of deaths (compared with 22% due to cancer) (30) . IHD also accounts for the vast majority of the mortality and morbidity of cardiac disease. Each year, Ͼ1.5 million patients have an MI. Many more are hospitalized for UA and evaluation and treatment of stable chest pain syndromes. Patients who have had ACS, such as acute MI, remain at risk for recurrent events even if they have no, or limited, symptoms, and they should be considered to have SIHD.
In approximately 50% of patients, angina pectoris is the initial manifestation of IHD (27) . The incidence of angina rises continuously with age in women, whereas the incidence of angina in men peaks between 55 and 65 years of age before declining (27) . It has been estimated that there are 30 patients with stable angina for every patient hospitalized with infarction, and symptoms in many of these patients are poorly controlled (31) (32) (33) . The direct and indirect costs of caring for patients with IHD are estimated to exceed $150 billion in the United States.
Organization of the Guideline
The overarching framework adopted in this guideline reflects the complementary goals of treating patients with known SIHD, alleviating or improving symptoms, and prolonging life. This guideline is divided into 4 basic In clinical practice, steps delineated in the algorithms often overlap. An essential principle that transcends all recommendations in this guideline is that of informing and involving patients in all decisions that affect them, directly or indirectly, as summarized in the following recommendation: 
Stress Testing and Advanced Imaging for Initial Diagnosis in Patients With Suspected SIHD Who Require Noninvasive Testing
See Table 4 for a summary of recommendations from this section. 2. Patients with SIHD should be educated about the following lifestyle elements that could influence prognosis: weight control, maintenance of a body mass index of 18.5 to 24.9 kg/m 2 , and maintenance of a waist circumference less than 102 cm (40 inches) in men and less than 88 cm (35 inches) in women (less for certain 1. All patients should be counseled about the need for lifestyle modification: weight control; increased physical activity; alcohol moderation; sodium reduction; and emphasis on increased consumption of fresh fruits, vegetables, and low-fat dairy products (24, (188) (189) (190) (191) (192) (193) (194) (195) (196) .
(Level of Evidence: B) 2. In patients with SIHD with blood pressure 140/90 mm Hg or higher, antihypertensive drug therapy should be instituted in addition to or after a trial of lifestyle modifications (197) (198) (199) (200) (201) (202) .
(Level of Evidence: A) 3. The specific medications used for treatment of high blood pressure should be based on specific patient characteristics and may include angiotensin-converting enzyme (ACE) inhibitors and/or beta block-ers, with addition of other drugs, such as thiazide diuretics or calcium channel blockers, if needed to achieve a goal blood pressure of less than 140/90 mm Hg (203, 204 1. PCI to improve survival is reasonable as an alternative to CABG in selected stable patients with significant (Ն50% diameter stenosis) unprotected left main CAD with: 1) anatomic conditions associated with a low risk of PCI procedural complications and a high likelihood of good long-term outcome (e.g., a low SYNTAX score [Յ22], ostial or trunk left main CAD); and 2) clinical characteristics that predict a significantly increased risk of adverse surgical outcomes (e.g., STS-predicted risk of operative mortality Ն5%) (322, 324, 325, (335) (336) (337) (338) (339) (340) (341) (342) (343) (344) (345) (346) (347) (348) (349) (350) (351) (352) (353) . (Level of Evidence: B) 2. PCI to improve survival is reasonable in patients with unstable angina/non-ST-elevation MI when an unprotected left main coronary artery is the culprit lesion and the patient is not a candidate for CABG (325, 340, (342) (343) (344) (349) (350) (351) (352) 354) . (Level of Evidence: B) 3. PCI to improve survival is reasonable in patients with acute STelevation MI when an unprotected left main coronary artery is the culprit lesion, distal coronary flow is less than TIMI (Thrombolysis In Myocardial Infarction) grade 3, and PCI can be performed more rapidly and safely than CABG (337, 355, 356) . PCI IIa-For SIHD when both of the following are present:
CAD Revascularization: Recommendations
• Anatomic conditions associated with a low risk of PCI procedural complications and a high likelihood of good long-term outcome (e.g., a low SYNTAX score of Յ22, ostial or trunk left main CAD)
• Clinical characteristics that predict a significantly increased risk of adverse surgical outcomes (e.g., STS-predicted risk of operative mortality Ն5%) (139, 334, (373) (374) (375) (376) . (Level of Evidence: B) 3. CABG with a left internal mammary artery graft to improve survival is reasonable in patients with significant (Ն70% diameter) stenosis in the proximal LAD artery and evidence of extensive ischemia (334, 360, 367, 368) . (Level of Evidence: B) 4. It is reasonable to choose CABG over PCI to improve survival in patients with complex 3-vessel CAD (e.g., SYNTAX score Ͼ22), with or without involvement of the proximal LAD artery who are good candidates for CABG (336, 353, (360) (361) (362) . (Level of Evidence: B) 5. CABG is probably recommended in preference to PCI to improve survival in patients with multivessel CAD and diabetes mellitus, particularly if a left internal mammary artery graft can be anastomosed to the LAD artery (365, 380, (381) (382) (383) (384) (385) (386) .
(Level of Evidence: B)
CLASS IIb 1. The usefulness of CABG to improve survival is uncertain in patients with significant (Ն70%) diameter stenoses in 2 major coronary arteries not involving the proximal LAD artery and without extensive ischemia (360) . (Level of Evidence: C) 2. The usefulness of PCI to improve survival is uncertain in patients with 2-or 3-vessel CAD (with or without involvement of the proximal LAD artery) or 1-vessel proximal LAD disease (140, 330, 358, 360) .
(Level of Evidence: B) 3. CABG might be considered with the primary or sole intent of improving survival in patients with SIHD with severe LV systolic dysfunction (ejection fraction Ͻ35%) whether or not viable myocardium is present (127, 139, 334, (373) (374) (375) (376) (377) . (Level of Evidence: B) 4. The usefulness of CABG or PCI to improve survival is uncertain in patients with previous CABG and extensive anterior wall ischemia on noninvasive testing (397) (398) (399) (400) (401) (408) (409) (410) (411) . 1. CABG or PCI to improve symptoms is beneficial in patients with 1 or more significant (Ն70% diameter) coronary artery stenoses amenable to revascularization and unacceptable angina despite GDMT (140, (387) (388) (389) (390) (391) (392) (393) 395, 396, 412) .
(Level of Evidence: A)
CLASS IIa 1. CABG or PCI to improve symptoms is reasonable in patients with 1 or more significant (Ն70% diameter) coronary artery stenoses and unacceptable angina for whom GDMT cannot be implemented because of medication contraindications, adverse effects, or patient preferences. (Level of Evidence: C) 2. PCI to improve symptoms is reasonable in patients with previous CABG, 1 or more significant (Ն70% diameter) coronary artery stenoses associated with ischemia, and unacceptable angina despite GDMT (397, 399, 400) . (Level of Evidence: C) 3. It is reasonable to choose CABG over PCI to improve symptoms in patients with complex 3-vessel CAD (e.g., SYNTAX score Ͼ22), with or without involvement of the proximal LAD artery, who are good candidates for CABG (325, 336, 353, (360) (361) (362) 1. CCTA for assessment of patency of CABG or of coronary stents 3 mm or larger in diameter might be reasonable in patients with known SIHD who have new or worsening symptoms not consistent with UA, irrespective of ability to exercise (439) (440) (441) (442) (443) . (Level of Evidence: B) 2. CCTA might be reasonable in patients with known SIHD who have new or worsening symptoms not consistent with UA, irrespective of ability to exercise, in the absence of known moderate or severe calcification or if the CCTA is intended to assess coronary stents less than 3 mm in diameter (55, 58, 439) . (Level of Evidence: B) CLASS III: No Benefit 1. CCTA should not be performed for assessment of native coronary arteries with known moderate or severe calcification or with coronary stents less than 3 mm in diameter in patients with known SIHD who have new or worsening symptoms not consistent with UA, irrespective of ability to exercise (439) (440) (441) (442) (443) . (Level of Evidence: B)
Noninvasive Testing in Known SIHD-Asymptomatic (or Stable Symptoms)
See Table 9 for a summary of recommendations from this section.
CLASS IIa
1. Nuclear MPI, echocardiography, or CMR with either exercise or pharmacological stress can be useful for follow-up assessment at 2-year or longer intervals in patients with SIHD with prior evidence of silent ischemia or who are at high risk for a recurrent cardiac event and a) are unable to exercise to an adequate workload, b) have an uninterpretable ECG, or c) have a history of incomplete coronary revascularization (10, 13, 20) . 
